Antimicrob Resist Infect Control:含以乙醇为基础的擦手凝胶在医护人员中的可接受性

2022-09-16 sunshine MedSci原创

医护人员经常因频繁进行手部卫生而出现皮肤干燥和刺激。配方的可接受性和耐受性低是手部卫生依从性的障碍,尽管很少有研究表明哪些特定类型的配方比其他配方具有更高的可接受性。

医护人员经常因频繁进行手部卫生而出现皮肤干燥和刺激。配方的可接受性和耐受性低是手部卫生依从性的障碍,尽管很少有研究表明哪些特定类型的配方比其他配方具有更高的可接受性。近日,发表于Antimicrob Resist Infect Control的一项研究比较了以乙醇为基础的擦手凝胶和以异丙醇为基础的配方(一种擦剂和一种凝胶配方)的可接受性和耐受性,目前瑞士日内瓦大学医院的医护人员使用这种配方。

研究共纳入42名参与者,随机分配到两个测试组中,以测试他们目前使用的异丙醇基配方(Hopirub®或Hopigel®),以及含有过脂剂的乙醇基配方(Saniswiss Sanitizer Hands H1)。参与者在7-10天的工作轮班中测试每种配方,之后评估皮肤状况并收集反馈意见。

结果显示,H1在皮肤干燥方面的得分明显优于对照配方(P = 0.0209),而且参与者在使用该配方时感觉到的手部不适感较少(P = 0.0448)。H1引起的皮肤干燥比Hopirub®/Hopigel®少(P = 0.0210)。尽管总体偏好相当两极化,但21名参与者更喜欢H1干预配方,17名参与者更喜欢他们在护理活动中通常使用的Hopirub®/Hopigel®配方。

综上所述,该研究发现,参与者对所测试配方的反应在可接受性方面存在差异,且偏好严重两极化。这些结果表明,让医护人员在不同的高质量产品中进行选择,对于确保最大的可接受性非常重要。还需要进行更多的研究,以确定当一个人使用对其具有高接受性的ABHR时,HCW手部卫生的依从性是否会明显增加。

原始出处:

Alexandra Peters, et al., Acceptability of an alcohol-based handrub gel with superfatting agents among healthcare workers: a randomized crossover controlled study. Antimicrob Resist Infect Control. 2022 Jul 15;11(1):97. doi: 10.1186/s13756-022-01129-4.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1858070, encodeId=1dd418580e091, content=<a href='/topic/show?id=3f48525849' target=_blank style='color:#2F92EE;'>#CRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5258, encryptionId=3f48525849, topicName=CRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Sat Nov 05 21:27:11 CST 2022, time=2022-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2084755, encodeId=07a12084e5535, content=<a href='/topic/show?id=61f411e013b' target=_blank style='color:#2F92EE;'>#Micro#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11701, encryptionId=61f411e013b, topicName=Micro)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Fri Mar 03 23:27:11 CST 2023, time=2023-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1278647, encodeId=3b5e12e86474a, content=<a href='/topic/show?id=d80c343e4fd' target=_blank style='color:#2F92EE;'>#医护人员#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=34374, encryptionId=d80c343e4fd, topicName=医护人员)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f34c147, createdName=ay2000fy, createdTime=Thu Sep 15 13:27:11 CST 2022, time=2022-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1461107, encodeId=4dd5146110ea5, content=<a href='/topic/show?id=de4331310a4' target=_blank style='color:#2F92EE;'>#凝胶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31310, encryptionId=de4331310a4, topicName=凝胶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e09e6383467, createdName=lishizhe, createdTime=Thu Sep 15 13:27:11 CST 2022, time=2022-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1588499, encodeId=fc6a158849977, content=<a href='/topic/show?id=1cb8e014e0' target=_blank style='color:#2F92EE;'>#ESI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7014, encryptionId=1cb8e014e0, topicName=ESI)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f4f817593223, createdName=skhzy, createdTime=Thu Sep 15 13:27:11 CST 2022, time=2022-09-15, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1858070, encodeId=1dd418580e091, content=<a href='/topic/show?id=3f48525849' target=_blank style='color:#2F92EE;'>#CRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5258, encryptionId=3f48525849, topicName=CRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Sat Nov 05 21:27:11 CST 2022, time=2022-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2084755, encodeId=07a12084e5535, content=<a href='/topic/show?id=61f411e013b' target=_blank style='color:#2F92EE;'>#Micro#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11701, encryptionId=61f411e013b, topicName=Micro)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Fri Mar 03 23:27:11 CST 2023, time=2023-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1278647, encodeId=3b5e12e86474a, content=<a href='/topic/show?id=d80c343e4fd' target=_blank style='color:#2F92EE;'>#医护人员#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=34374, encryptionId=d80c343e4fd, topicName=医护人员)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f34c147, createdName=ay2000fy, createdTime=Thu Sep 15 13:27:11 CST 2022, time=2022-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1461107, encodeId=4dd5146110ea5, content=<a href='/topic/show?id=de4331310a4' target=_blank style='color:#2F92EE;'>#凝胶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31310, encryptionId=de4331310a4, topicName=凝胶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e09e6383467, createdName=lishizhe, createdTime=Thu Sep 15 13:27:11 CST 2022, time=2022-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1588499, encodeId=fc6a158849977, content=<a href='/topic/show?id=1cb8e014e0' target=_blank style='color:#2F92EE;'>#ESI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7014, encryptionId=1cb8e014e0, topicName=ESI)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f4f817593223, createdName=skhzy, createdTime=Thu Sep 15 13:27:11 CST 2022, time=2022-09-15, status=1, ipAttribution=)]
    2023-03-03 xjy02
  3. [GetPortalCommentsPageByObjectIdResponse(id=1858070, encodeId=1dd418580e091, content=<a href='/topic/show?id=3f48525849' target=_blank style='color:#2F92EE;'>#CRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5258, encryptionId=3f48525849, topicName=CRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Sat Nov 05 21:27:11 CST 2022, time=2022-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2084755, encodeId=07a12084e5535, content=<a href='/topic/show?id=61f411e013b' target=_blank style='color:#2F92EE;'>#Micro#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11701, encryptionId=61f411e013b, topicName=Micro)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Fri Mar 03 23:27:11 CST 2023, time=2023-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1278647, encodeId=3b5e12e86474a, content=<a href='/topic/show?id=d80c343e4fd' target=_blank style='color:#2F92EE;'>#医护人员#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=34374, encryptionId=d80c343e4fd, topicName=医护人员)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f34c147, createdName=ay2000fy, createdTime=Thu Sep 15 13:27:11 CST 2022, time=2022-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1461107, encodeId=4dd5146110ea5, content=<a href='/topic/show?id=de4331310a4' target=_blank style='color:#2F92EE;'>#凝胶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31310, encryptionId=de4331310a4, topicName=凝胶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e09e6383467, createdName=lishizhe, createdTime=Thu Sep 15 13:27:11 CST 2022, time=2022-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1588499, encodeId=fc6a158849977, content=<a href='/topic/show?id=1cb8e014e0' target=_blank style='color:#2F92EE;'>#ESI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7014, encryptionId=1cb8e014e0, topicName=ESI)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f4f817593223, createdName=skhzy, createdTime=Thu Sep 15 13:27:11 CST 2022, time=2022-09-15, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1858070, encodeId=1dd418580e091, content=<a href='/topic/show?id=3f48525849' target=_blank style='color:#2F92EE;'>#CRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5258, encryptionId=3f48525849, topicName=CRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Sat Nov 05 21:27:11 CST 2022, time=2022-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2084755, encodeId=07a12084e5535, content=<a href='/topic/show?id=61f411e013b' target=_blank style='color:#2F92EE;'>#Micro#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11701, encryptionId=61f411e013b, topicName=Micro)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Fri Mar 03 23:27:11 CST 2023, time=2023-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1278647, encodeId=3b5e12e86474a, content=<a href='/topic/show?id=d80c343e4fd' target=_blank style='color:#2F92EE;'>#医护人员#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=34374, encryptionId=d80c343e4fd, topicName=医护人员)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f34c147, createdName=ay2000fy, createdTime=Thu Sep 15 13:27:11 CST 2022, time=2022-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1461107, encodeId=4dd5146110ea5, content=<a href='/topic/show?id=de4331310a4' target=_blank style='color:#2F92EE;'>#凝胶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31310, encryptionId=de4331310a4, topicName=凝胶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e09e6383467, createdName=lishizhe, createdTime=Thu Sep 15 13:27:11 CST 2022, time=2022-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1588499, encodeId=fc6a158849977, content=<a href='/topic/show?id=1cb8e014e0' target=_blank style='color:#2F92EE;'>#ESI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7014, encryptionId=1cb8e014e0, topicName=ESI)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f4f817593223, createdName=skhzy, createdTime=Thu Sep 15 13:27:11 CST 2022, time=2022-09-15, status=1, ipAttribution=)]
    2022-09-15 lishizhe
  5. [GetPortalCommentsPageByObjectIdResponse(id=1858070, encodeId=1dd418580e091, content=<a href='/topic/show?id=3f48525849' target=_blank style='color:#2F92EE;'>#CRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5258, encryptionId=3f48525849, topicName=CRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Sat Nov 05 21:27:11 CST 2022, time=2022-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2084755, encodeId=07a12084e5535, content=<a href='/topic/show?id=61f411e013b' target=_blank style='color:#2F92EE;'>#Micro#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11701, encryptionId=61f411e013b, topicName=Micro)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Fri Mar 03 23:27:11 CST 2023, time=2023-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1278647, encodeId=3b5e12e86474a, content=<a href='/topic/show?id=d80c343e4fd' target=_blank style='color:#2F92EE;'>#医护人员#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=34374, encryptionId=d80c343e4fd, topicName=医护人员)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f34c147, createdName=ay2000fy, createdTime=Thu Sep 15 13:27:11 CST 2022, time=2022-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1461107, encodeId=4dd5146110ea5, content=<a href='/topic/show?id=de4331310a4' target=_blank style='color:#2F92EE;'>#凝胶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31310, encryptionId=de4331310a4, topicName=凝胶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e09e6383467, createdName=lishizhe, createdTime=Thu Sep 15 13:27:11 CST 2022, time=2022-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1588499, encodeId=fc6a158849977, content=<a href='/topic/show?id=1cb8e014e0' target=_blank style='color:#2F92EE;'>#ESI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7014, encryptionId=1cb8e014e0, topicName=ESI)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f4f817593223, createdName=skhzy, createdTime=Thu Sep 15 13:27:11 CST 2022, time=2022-09-15, status=1, ipAttribution=)]
    2022-09-15 skhzy

相关资讯

Nat Nanotechnol:研发纳米喷胶,有望抑制术后肿瘤复发

今日,《自然》子刊《自然·纳米技术》(Nature Nanotechnology)在线刊登了一项创新抗癌研究:加州大学洛杉矶分校(UCLA)华人学者顾臻教授与其团队开发出了一种新型癌症免疫治疗策略。通过在肿瘤切除部位喷洒喷雾,快速形成凝胶,并通过包埋其中的纳米颗粒缓释抗体药物,研究人员在动物模型上验证了该种喷剂能靶向手术后的残余癌细胞,显着抑制癌症复发和潜在的转移。

医美前沿解读:Skinbooster韩国研究-改善皮肤质量的证据

皮肤作为人体最大的器官覆盖全身,从美容和抗衰的角度出发,皮肤质量被看作为一个非常重要的因素,细腻、通透、水润的皮肤状态使得外表更加年轻化。

J Contemp Dent Pract:新型局部用凝胶可用于治疗口腔溃疡

复发性或偶发性口疮性是一种疼痛明显的口腔疾病,患病率很高。由于病因尚不清楚,并且很可能与局部免疫系统功能障碍有关,因此已提出了几种治疗策略,包括全身性药物,局部药物和激光疗法,以减轻患者的疼痛和不适,

Int Wound J:洋葱提取物凝胶在疤痕管理方面并不优于其他外用疗法

皮肤疤痕是由伤口愈合过程中胶原蛋白的过度沉积造成的,这是对热、手术后和创伤的异常反应。某些情况下,疤痕会变得肥厚或导致瘢痕疙瘩。洋葱提取物(OE)的抗炎、抗菌、抗增殖和再生活性的报道,其凝胶模式已在临

Sci Tran Med:神奇水凝胶,癌症转移与复发的“克星”!

开创性的研究揭示了一种有前途的策略来阻止癌症的复发,并且它以可生物降解的凝胶的形式出现。

J Periodontol:龈下给药1.2%罗伐他汀与1%二甲双胍凝胶治疗慢性牙周炎的研究

本文旨在研究和比较局部给药的1.2%瑞舒伐他汀(RSV)和1%二甲双胍(MF)凝胶作为刮治和根面平整(SRP)辅助治疗慢性牙周炎牙槽骨吸收的临床疗效。